This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
March 27, 2024
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa
March 27, 2024
Vicore publishes the Annual Report for 2023
March 26, 2024
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
March 19, 2024
HealthCap portfolio company Fusion Pharmaceuticals to be acquired by AstraZeneca for up to USD 2.4 billion
March 19, 2024
Fusion Pharmaceuticals To Be Acquired By AstraZeneca, Accelerating Development Of Next-Generation Radioconjugates To Treat Cancer
March 19, 2024
Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis
March 14, 2024
BONESUPPORT – CERAMENT® G RECEIVES FDA CLEARANCE FOR OPEN FRACTURES
March 13, 2024
Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH
March 13, 2024
Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
March 13, 2024
Oncopeptides carries out a fully guaranteed rights issue of approximately SEK 300 million to reach profitability during 2026